Best Biotech Stocks To Buy In Q2 2021

Best Biotech Stocks

Technology has changed just about every aspect of our lives. The way we travel, communicate, and even enjoy entertainment has been transformed. One of the biggest, yet most under-realized, transformations we’ve seen is in the biotechnology industry.  Ailments that were a death sentence just decades ago are now able to be treated, and in many … Read more

Affimed (AFMD) Stock Rockets On Data

Affimed AFMD Stock News

Affimed NV (NASDAQ: AFMD) is running for the top in the market this morning, and for good reason. The company announced positive initial clinical data surrounding AFM13, a drug under development for the treatment of cancer. Here’s the scoop: Affimed Announces Positive Clinical Data In the press release, Affimed announced positive initial data from a … Read more

Affimed (AFMD) Stock: Continues Skyward On Roche Collaboration

Affimed NV (NASDAQ: AFMD) is following up on yesterday’s gains in multiples with more strong gains in the market today. So, what’s going on? The comapny announced yesterday in the pre market that it had entered into a collaboration with Roche’s Genentech subsidiary. Of course, the news excited investors, sending the stock soaring. Today, we’ll … Read more

Affimed (AFMD) Stock: Gaining In Multiples On Collaboration News

Affimed NV (NASDAQ: AFMD) is flying early on in the market this morning, and for good reason. The company announced that it has entered into a collaboration agreement with a member of Roche Group, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The collaboration agreement; what we’re seeing from … Read more

Affimed (AFMD) Stock: Gaining Big On Clinical Data

Affimed N.V. (NASDAQ: AFMD) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced clinical data from two separate trials, leading to excitement among investors and sending the stock for the top. Today, we’ll talk about the data, what we’re seeing from the stock, and what we’ll … Read more